OBJECTIVE: To test the efficacy and tolerability of long-term administration of the angiotensin converting enzyme inhibitor, benazepril, in dogs with heart failure. METHODS: The study was a prospective, randomized, double-blind, placebo-controlled clinical trial involving 16 centers in France, Italy, Switzerland and UK. A total of 162 dogs with class II and III (ISACHC classification) heart failure caused by chronic valvular disease (CVD) or dilated cardiomyopathy (DCM) were enrolled. Benazepril (minimum dosage, 0.25 mg/kg) or placebo were administered orally once daily for up to 34 months, either alone or as add-on therapy to "standard therapy" i.e. diuretics and/or digoxin and/or anti-arrhythmic drugs. RESULTS: The mean survival time (to death or withdrawal from the study due to worsening of heart failure) was 2.7 times longer in the benazepril treated group (428 days) as compared with the placebo group (158 days). Differences reached statistical significance (p<0.05 Cox proportional hazards model, 44% reduction in risk). The survival rate after one year was 49% with benazepril and 20% with placebo. Benazepril produced a statistically significant (p<0.05) reduction (by 46%) in the risk of worsening of heart failure (to ISACHC class III) when therapy was initiated early (in ISACHC class II). In sub-group analyses, a statistically significant (p<0.05) benefit of benazepril was reached for both survival and worsening endpoints for dogs with CVD (n=125), but not for the small sample of dogs with DCM (37). Benazepril also improved the exercise tolerance and global clinical condition at day 28 (p<0.05). As compared to the placebo group, dogs treated with benazepril presented with the same frequency of undesirable clinical events and fewer biochemical disturbances (less frequent increases in plasma urea or creatinine and decreases in plasma potassium). CONCLUSIONS: Benazepril extended the useful life-span of dogs with ISACHC class II and III heart failure (due to CVD) and was well tolerated.
OBJECTIVE: To test the efficacy and tolerability of long-term administration of the angiotensin converting enzyme inhibitor, benazepril, in dogs with heart failure. METHODS: The study was a prospective, randomized, double-blind, placebo-controlled clinical trial involving 16 centers in France, Italy, Switzerland and UK. A total of 162 dogs with class II and III (ISACHC classification) heart failure caused by chronic valvular disease (CVD) or dilated cardiomyopathy (DCM) were enrolled. Benazepril (minimum dosage, 0.25 mg/kg) or placebo were administered orally once daily for up to 34 months, either alone or as add-on therapy to "standard therapy" i.e. diuretics and/or digoxin and/or anti-arrhythmic drugs. RESULTS: The mean survival time (to death or withdrawal from the study due to worsening of heart failure) was 2.7 times longer in the benazepril treated group (428 days) as compared with the placebo group (158 days). Differences reached statistical significance (p<0.05 Cox proportional hazards model, 44% reduction in risk). The survival rate after one year was 49% with benazepril and 20% with placebo. Benazepril produced a statistically significant (p<0.05) reduction (by 46%) in the risk of worsening of heart failure (to ISACHC class III) when therapy was initiated early (in ISACHC class II). In sub-group analyses, a statistically significant (p<0.05) benefit of benazepril was reached for both survival and worsening endpoints for dogs with CVD (n=125), but not for the small sample of dogs with DCM (37). Benazepril also improved the exercise tolerance and global clinical condition at day 28 (p<0.05). As compared to the placebo group, dogs treated with benazepril presented with the same frequency of undesirable clinical events and fewer biochemical disturbances (less frequent increases in plasma urea or creatinine and decreases in plasma potassium). CONCLUSIONS:Benazepril extended the useful life-span of dogs with ISACHC class II and III heart failure (due to CVD) and was well tolerated.
Authors: Jonathan P Mochel; Martin Fink; Mathieu Peyrou; Antoine Soubret; Jérôme M Giraudel; Meindert Danhof Journal: Pharm Res Date: 2014-12-02 Impact factor: 4.200
Authors: Maria Fernanda de M Costa; Adriana K Carmona; Marcio F M Alves; Timothy M Ryan; Helen M Davies; Garry A Anderson; Ron F Slocombe Journal: J Vet Sci Date: 2011-03 Impact factor: 1.672
Authors: J L Pouchelon; C E Atkins; C Bussadori; M A Oyama; S L Vaden; J D Bonagura; V Chetboul; L D Cowgill; J Elliot; T Francey; G F Grauer; V Luis Fuentes; N Sydney Moise; D J Polzin; A M Van Dongen; N Van Israël Journal: J Small Anim Pract Date: 2015-09 Impact factor: 1.522